Treatment of chronic viral hepatitis

Antiviral Chemistry and Chemotherapy

Volumn 9, Issue 6, 1998, Pages 449-460

  Main, J ^a   McCarron, B ^a   Thomas, H C ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Hepatitis B; Hepatitis C; Interferon

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; AMANTADINE; BETA INTERFERON; FAMCICLOVIR; FIALURIDINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; LAMIVUDINE; LOBUCAVIR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NUCLEOSIDE ANALOG; PARACETAMOL; PENCICLOVIR; RIBAVIRIN; THYMUS PEPTIDE; VIDARABINE;

ANTIVIRAL ACTIVITY; BONE MARROW TOXICITY; CELL CULTURE; CHRONIC HEPATITIS; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG EFFICACY; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEMOLYSIS; HEPATITIS B; HEPATITIS C; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER FAILURE; MYALGIA; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0031791594     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029800900601     Document Type: Review

References (110)

1. Agnello V, Chung RT & Kaplan LM (1992) A role for hepatitis C virus infection in type II cryoglobulinemia. New England Journal of Medicine 327:1490-1495.
2. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A & McMillan J (1997) Hepatitis B virus polymerase mutations during antiviral therapy in a patient following transplantation. Journal of Hepatology 26:1148-1153.
3. Bartenschlager R (1997) Molecular targets in inhibition of hepatitis C virus replication. Antiviral Chemistry & Chemotherapy 8:281-301.
4. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay L, Tzakis AG, Schiff ER & Brown N (1997) Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349:20-22.
5. Bassendine MF, Chadwick RG & Salmeron J (1981) Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study. Gastroenterology 80:1016-1021.
6. Bellobuono A, Mondazzi L, Tempini SGB, Cassara L, Lombino M, Silini E, Bono F, & Ideo G (1994) Efficacy of different regimens of alpha interferon in chronic hepatitis C and relationship between response and HCV genotype. Journal of Hepatology (Suppl.) 21:35.
7. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG & Davis GL (1997) Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Annals of Internal Medicine 127:855-865.
8. Bisollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M & Baulieux J (1997) Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 26:500-504.
9. Bloomer J, Can R, Sherman M, Ingraham P & DeHertog D (1997) A preliminary study of lobucavir for chronic hepatitis B. Hepatology 25:A1199.
10. Bodenheimer HC, Lindsay KL, Davis GL, Lewis JH, Thung SN & Seeff LB (1997) Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 26:473-477.
11. Bodsworth NJ, Cooper DA & Donovan B (1991) The influence of human immunodeficiency virus type 1 on the development of the hepatitis B virus carrier state. Journal of Infectious Diseases 163:1138-1140.
12. Booth JCL, Foster GR, Kumar U, Galassini R, Goldin RD, Brown JL & Thomas HC (1995) Chronic hepatitis C virus infection: predictive value of genotype and level of viraemia on disease progression and response to interferon alpha. Gut 36:427-432.
13. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M & Barbara L (1994) A pilot study of combination therapy with ribavirin plus interferon alfa for interferon resistant chronic hepatitis C. Gastroenterology 107:812-817.
14. Brook MG, Chan G, Yap I, Karayiannis P, Lever AM, Jacyna M, Main J & Thomas HC (1989) Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection. British Medical Journal 299:652-656.
15. Brugger SA, Oesterreicher C, Hofmann J, Kalhs P, Greinix HT & Muller C (1997) Hepatitis B virus clearance by transplantation of bone marrow from hepatitis B immunised donor. Lancet 349:996-997.
16. Brunetto MR, Oliveri F, Colombatto P, Capalbo M, Barbera C & Bonino F (1995) Treatment of chronic anti-HBe positive hepatitis B with interferon alpha. Journal of Hepatology 22 (Suppl. 1):42-44.
17. Camps J, Garcia N, Riezu-Boj JI, Civeira MP & Prieto J (1993) Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. Journal of Hepatology 19:408-412.
18. Carman WF, Jacyna MR, Hadziyannis S & Karayiannis P, McGarvey MJ, Makris A & Thomas HC (1989) Mutation preventing formation of hepatitis HB e antigen in chronic hepatitis B virus infection. Lancet ii:588-591.
19. Carreno V & Quiroga JA (1997) Biological properties of interleukin-12 and its therapeutic use in persistent hepatitis B and hepatitis C virus infection. Journal of Viral Hepatitis 4:1419-1425.
20. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY & Chen DS (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. New England Journal of Medicine 336: 1855-1859.
21. Chemello L, Alberti A, Rose K & Simmonds P (1994a) Hepatitis C serotype and response to interferon therapy. New England Journal of Medicine 330:143.
22. Chemello L, Cavaletto L, Bernardinello E, Silvestri E, Benvegnu L, Pontisso P & Alberti A (1994b) Response to ribavirin, to interferon and to a combination of both in patients with chronic hepatitis C and its relation to HCV genotypes. Journal of Hepatology (supplement 1) 21:S12.
23. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P & Alberti A (1995) The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. Journal of Hepatology 23:8-12
24. Chemello L, Cavaletto L, Donada C, Bonetti P, Casari P & Urban F (1997) Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology 113:1654-1659.
25. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW & Houghton M (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-62.
26. Colledge D, Locarnini S & Shaw T (1997) Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir. Hepatology 26:216-225.
27. Colucci G & Gitekunst K (1997) Development of quantitative PCR assay for monitoring HCV viraemia levels in patients with chronic hepatitis C. Journal of Viral Hepatology 4:75-78.
28. Davis GL (1994) Prediction of response to interferon treatment of chronic hepatitis C. Journal of Hepatology 21:1-3.
29. Davis GL, Balart LA & Schiff ER (1989) Treatment of chronic hepatitis C with recombinant interferon alpha. New England Journal of Medicine 321:1501-1506.
30. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM & Hoofnagle JH (1989) Recombinant interferon alfa therapy for chronic hepatitis C: a randomized double blind placebo-controlled trial. New England Journal of Medicine 321:1506-1510.
31. Di Bisceglie AM, Shindo M, Fong T-L, Fried MW, Swain MG, Bergasa NV, Axiotis CA, Waggoner JG, Park Y & Hoofnagle JH (1992) A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16:649-654.
32. Di Bisceglie AM, Bacon BR, Kleiner DE & Hoofnagle JH (1994) Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. Journal of Hepatolology 21:1109-1112.
33. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, ParkY & Yurdaydin C (1995) Ribavirin as therapy for chronic hepatitis C. Annals of Internal Medicine 123:897-903.
34. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C & Rubin M (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. New England Journal of Medicine 333:1657-1661.
35. Duflot A, Mehrotra R, Yu SZ, Barraud L, Trepo C & Cova L (1995) Spectrum of liver disease and duck hepatitis B virus infection in a large series of Chinese ducks with hepatocellular carcinoma. Hepatology 21:1483-1491
36. Enomoto N, Sakuma IYA, Kuorsaki M, Murakami T, Yamamoto C, Izumi N, Marumo F & Sato C (1995) Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Journal of Clinical Investigation 96:224-230.
37. Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, Kuritzkes DR, Fallon MA & Rubin M (1995) Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. New England Journal of Medicine 333:1662-1669.
38. Fargion S, Fracanzani AL, Sampietro M, Molteni V, Bolorini R & Mattioli M (1997) Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. European Journal of Gastroenterology and Hepatology 9:497-503.
39. Fattovich G, Giustina G, Alberti A, Guido M, Pontisso P, Favarato S, Benvegnu L & Ruol A (1994) A randomised controlled trial of thymopentin therapy in patients with chronic hepatitis B. Journal of Hepatology 21:361-366.
40. Fattovich G, Giustina G, Realdi G, Corrocher R & Schalm SW (1997) European concerted action on viral hepatitis. Long term outcome of hepatitis B e antigen positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 26:1338-1342.
41. Feray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, Reynes M, Okamoto H, Bismuth H & Brechot C (1995) Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 108:1088-1096.
42. Foster GR, Goldin RD, Main J, Murray-Lyon I, Hargreaves S & Thomas HC (1997) Management of chronic viral hepatitis C; clinical audit of biopsy based management algorithm. British Medical Journal 315:453-458
43. Foster GR, Goldin RD & Thomas HC (1998) Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 27:209-212
44. Garcia G, Smith CI, Weissberg JI, Eisenberg M, Bissett J, Nair PV, Mastre B, Rosno S, Roskamp D, Waterman K, Pollard RB, Tong MJ, Brown BW, Robinson WS, Gregory PB & Merigan TC (1987) Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. Annals of Internal Medicine 107:278-285.
45. Gavier B, Martinez-Gonzalez MA, Riezu-Bpj JI, Lasarte JJ, Garcia N, Civeira MP & Prieto J (1997) Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 113:1647-1653.
46. Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS & Merigan TC (1976) Effect of human leucocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. New England Journal of Medicine 295:517-522.
47. Hadler SC, Judson FN, O'Malley PM, Altman NL, Penley K, Buchbinder S, Schable CA, Coleman PJ, Ostrow DN & Francis DP (1991) Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. Journal of Infectious Diseases 163:454-459.
48. Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L & Papaioannou C (1990) Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. Journal of Hepatology 11:S133-136.
49. Hayashi J, Kishihara T, Ueno K, Yamaji K, Kawakami Y & Furusyo N (1998) Age-related response to inteferon alfa in women vs men with chronic hepatitis C virus infection. Archives of Internal Medicine 158:177-181.
50. Heijtink RA, Kruining J, Honkoop P, Kuhns MC, Hop WCJ, Osterhaus ADME & Schalm SW (1997) Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B. Journal of Medical Virology 53:282-287.
51. Hino K, Okuda M, Konishi T, Ichiko H & Okita K (1995) Serial assay of hepatitis C virus RNA in serum for predicting response to interferon alpha therapy. Digestive Disease Sciences 40:14-20.
52. Hofgartner WT, Polyak SJ, Sullivan DG, Cairthers RL & Gretch DR (1997) Mutations in the NS5A gene of hepatitis C virus in North American patients infected with hepatitis C genotype 1a or 1b. Journal of Medical Virology 53:118-126.
53. Honkoop P, Deman RA, Scholte HR, Zondervan PE, van den Berg JWO, Rademakers LHPM & Schalm SW (1997a) Effect of lamivudine on morphology and function of mitcohondria in patients with chronic hepatitis B. Hepatology 26:211-215.
54. Honkoop P, Niesters HGM, de Man RAM, Osterhaus ADME & Schalm SW (1997b) Lamivudine resistance in immunocompetent chronic hepatitis B-incidence and patterns. Journal of Hepatology 26:1393-1395.
55. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y & Jones EA (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. New England Journal of Medicine 315:1575-1578.
56. Ide T, Sata M, Suzuki H, Uchimura Y, Shirachi M, Adachi N & Tanikawa K (1997) Characteristics of complete responders to interferon among patients with chronic hepatitis C with high serum levels of RNA. Hepatology Research 7:19-27.
57. International Interferon-α Hepatocellular Carcinoma Study Group. (1998). Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 351:1535-1539.
58. Jacyna MR, Brooks MG, Loke RHT, Main J, Murray-Lyon IM & Thomas HC (1989) Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A, non-B hepatitis. British Medical Journal 298:80-82.
59. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Harwell P, Couser WG, Corey L, Wener MH, Alpers CE et al. (1993). Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. New England Journal of Medicine 328:465-470.
60. Jouet P, Roudot-Thorval F, Dhumeaux D, Metreau J-M et Le Groupe Francais pour l'etude du traitement des hepatites chroniques NANB/C (1994) Comparative efficacy of interferon alfa in cirrhotic and non-cirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 106:686-690.
61. Kanai K, Kato M & Okamato H (1992) HCV genotypes in chronic hepatitis C and response to interferon. Lancet 339:1543.
62. Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW & Gross JB (1997) Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Annals of Internal Medicine 127:866-874.
63. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM & Hoofnagle JH (1991) Long term remissions of chronic hepatitis B after alpha interferon. Annals of Internal Medicine 114:629-634.
64. Lai CL, Lok ASF, Lin HJ et al. (1987) Placebo-controlled trial of recombinant alfa2 interferon (rIFN) in Chinese HBsAg carrier children. Lancet ii:877-880.
65. Lai M-Y, Kao J-H, Yang P-M, Wang J-T, Chen P-J & Chan K-W (1996) Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 111:1307-1312.
66. Lai C-L, Liaw Y-F, Leung N, Deslauriers M, Barnard J, Santhanan L et al. (1997) Genotypic resistance to lamivudine in a prospective, placebo-controlled multicentre study in Asia of lamivudine therapy for chronic hepatitis B infection: incidence, kinetics of emergence and correlation with disease parameters. Hepatology 26:522.
67. Lai C-L, Chien R-N, Leung N, Chang T-T, Guan R, Tai D-I, Ng K-Y, Wu P-C, Dent JC, Barber J, Stephenson SL & Gray DF (1998) A one year trial of lamivudine for chronic hepatitis B. New England Journal of Medicine 339:61-68.
68. Lampertico P, del Nonno E, Manzin A, Donato MF, Rumi MG & Lunghi G (1997) A randomised controlled trial of a 24 month course of interferon afa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 26:1621-1625.
69. Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P & Hoofnagle JH (1997a) Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113:1660-1667.
70. Lau GKK, Lok ASF, Liang RHS, Lai CL, Chiu EKW & Lau YL (1997b) Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immmunity transfer. Hepatology 25:1497-1501.
71. Lee CL & Ko YC (1997) Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. Pediatrics 99:351-353.
72. Lee J-H, von Wagner M, Roth WK, Teuber G, Sarrazin C & Zeuzem S (1998) Effect in ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. Journal of Hepatology 29:29-35.
73. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko G & Harrison TJ (1996) Selection of mutations in the hepatitis B virus polymerase during treatment of transplant recipients with lamivudine. Hepatology 24:711-713.
74. Main J, Brown JL, Howells C, Galassini R, Crossey M, Karayiannis P, Georgiou P, Atkinson G & Thomas HC (1996) A double blind placebo-controlled study to assess the effect of famciclovir in virus replication in patients with chronic hepatitis B virus infection. Journal of Viral Hepatitis 3:211-215.
75. Marcellin P, Giuily N, Loriot MA, Durand F, Samuel D & Bettan L (1997) Prolonged interferon-alpha therapy of hepatitis B virus related decompensated cirrhosis. Viral Hepatitis 4:21-26.
76. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, Pruett T, Stotka JL, Straus SE & Hoofnagle JH (1995) Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. New England Journal of Medicine 333:1099-1105.
77. Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, Lemonnier C, Degott C, Erlinger S & Benhamou JP (1995) Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 109:156-165.
78. Milella M, Antonelli G, Santantonio T, Currenti M, Monno L, Mariano N, Angarano G, Dianzani F & Pastore G (1993) Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver 13:146-150.
79. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J & Sullivan MT (1997) Lamivudine therapy for chronic hepatitis B; a six month randomised dose-ranging study. Gastroenterology 113:1258-1263.
80. Niederau C, Heintges T, Lange S, Goldman G, Niederau CM, Mohr L & Haussinger D (1996) Long-term follow-up of HBeAg positive patients treated with interferon alfa for chronic hepatitis B. New England Journal of Medicine 334:1422-1427.
81. NIH Consensus Group (1997) National Institute of Health consensus development conference panel statement: management of hepatitis C. Hepatology 26 (Suppl. 1):2S-10S.
82. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K & Otani S (1995) Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051-1055
83. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC & McDade H (1996) Viral dynamics in hepatitis B virus infection. Proceedings of the National Academy of Sciences, USA 93:4398-4402.
84. Olano JP, Borucki MJ, Wen JW & Haque AK (1995) Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clinical Infectious Diseases 21:973-976.
85. Penna A, del Prete G, Cavalli A, Bertoletti A, D'Elios MM & Sorrentino R (1997) Predominant T-helper cytokine profile of hepatitis B virus nucleocapsid-specific T cellls in acute self-limited hepatitis B. Hepatology 25:1022-1027.
86. Perrillo R, Regenstein F, Bodicky C, Campbell CJ & Sunwoo YC (1985) Comparative efficacy of adenine arabinoside 5′-monophosphate and prednisone withdrawal followed by adenine arabinoside 5'-monophosphate in the treatment of chronic active hepatitis type B. Gastroenterology 88:780-786.
87. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC, Lindsay K, Payne J, Dienstag JL, O'Brien C, Tamburro C, Jacobson IM, Sampliner R, Feit D, Lefkowitch JL, Kuhns M, Meschievitz C, Sanghvi B, Albrecht J & Gibas A (1990) A randomised controlled trial of interferon alfa 2-b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. New England Journal of Medicine 323:295-301.
88. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM, Vidaud M & Chaput JC (1995) A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. New England Journal of Medicine 332:1457-1462.
89. Protzer-Kolle U, Naumann U, Bartenschlager R, Berg T, Hopf U & Meyer zum Buschenfelde KH (1998) Hepatitis B virus with anti-genically altered hepatitis B surface antigen is selected by high dose hepatitis B immune globulin after liver transplantation. Hepatology 27:254-263.
90. Reichard O, Andersson J, Schvarcz R & Weiland O (1991). Ribavirin treatment for chronic hepatitis C. Lancet 337:1058-1061.
91. Reichard O, Foberg U, Fryden A, Mattson L, Norkrans G, Sonnerborg A, Wejstal R, Yun Z-B & Weiland O (1994) High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-a2b for 60 weeks. Hepatology 19:280-285.
92. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A & Weiland O (1998) Randomised, double-blind, placebo-controlled trial of interferon alpha 2b with and without ribavirin for chronic hepatitis C. Lancet 352:83-87.
93. Rollino C, Roccatello D, Giachino O, Basolo B & Piccoli G (1991) Hepatitis C virus infection and membranous glomerulonephritis. Nephron 59:319-320.
94. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou J-P & Bismuth H (1993) Liver transplantation in European patients with the hepatitis B surface antigen. New England Journal of Medicine 329:1842-1847.
95. Sangiovanni A, Morales R, Spinzi G, Rumi M, Casraghi A & Ceriani R (1998) Interferon alpha treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomised controlled trial. Hepatology 27:853-856.
96. Scullard GH, Pollard RB, Smith JL, Sacks SL, Gregory PB, Robinson WS & Merigan TC (1981) Antiviral treatment of chronic hepatitis B virus infection. Changes in viral markers with interferon combined with adenine arabinoside. Journal of Infectious Diseases 143:772-783.
97. Sells MA, Chen M & Acs G (1987) Production of hepatitis B virus particles in hepG2 cells transfected with cloned hepatitis B virus DNA. Proceedings of the National Academy of Sciences, USA 84:1005-1009.
98. Severini A, Liu X-Y, Wilson J & Tyrrell D (1995) Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-ß-L-2′, 3′ dideoxy-3′-thiacytidine. Antimicrobial Agents and Chemotherapy 39:1430-1435.
99. Singh N, Gayowski T, Wannstedt CF, Wagener CF, Wagener MM & Marino IR (1997) Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation 63:1415-1419.
100. Smith JP (1997) Treatment of chronic hepatitis C with amantadine. Digestive Disease Sciences 42:121-129.
101. Squadrito G, Leone F, Sartori M, Nalpas B, Berthelot P & Raimondo G (1997) Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C virus to interferon alfa. Gastroenterology 113:567-572.
102. Summers J, Smolec JM, Snyder R (1978) A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proceedings of the National Academy of Sciences, USA 75:4533-4537
103. Tennant BC & Gerin GL (1994) The woodchuck model of hepatitis B virus infection. In The Liver: Biology and Pathobiology, pp. 1455-1466. New York Raven Press.
104. Thursz M, Kwiatowski D, Allsopp CE, Greenwood BM & Thomas HC (1995) Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. New England Journal of Medicine 332:1065-1069.
105. Tong MJ, Blatt LM, McHutchison JG, Co RL & Conrad A (1997) Prediction of response during interferon alfa 2b therapy in chronic hepatitic C using viral and biochemical characteristics: a comparison. Hepatology 26:1640-1645.
106. Trepo C, Hantz O, Ouzan D, Fontagnes T et al. (1984) Therapeutic efficacy of adenine arabinoside monophosphate in symptomatic HBeAg positive chronic active hepatitis: a randomised placebo controlled study. Hepatology 4:1055-1061.
107. Trepo C, Jezek P, Atkinson GF & Boon RJ on behalf of the FCV chronic hepatitis B study group. (1997) Long term efficacy of famciclovir (FCV) in chronic hepatitis B: results of a phase IIB study. Journal of Hepatology 26 (Suppl. 1): abstract WP3/22.
108. Tsai NCS, Zuckerman E, Han SH, Goad K, Redeker AG & Fong TL (1997) Effect of iron depletion on long-term response to interferon-alpha therapy in patients with chronic hepatitis C who previously did not respond to interferon therapy. American Journal of Gastroenterology 92:1831-1834.
109. Tyrrell DLJ, Mitchell MC, De Man RA, Schalm SW, Main J, Thomas HC, Fevery J, Nevens F, Beranek P & Vicary C (1993) Phase II trial of lamivudine for chronic hepatitis B. Hepatology (Suppl.) 18:112A.
110. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, Shibata M & Morishima T (1992). Detection of hepatitis C virus by polymerase chain reaction and response to interferon alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 16:293-299.